Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma Group Limited has entered into a scheme implementation deed with Cosette Pharmaceuticals, Inc., where Cosette will acquire 100% of Mayne Pharma shares at A$7.40 per share, a premium to the current stock price. The acquisition is expected to enhance shareholder value and strengthen Mayne Pharma’s presence in the US dermatology and women’s health markets. The transaction is subject to shareholder and regulatory approvals, and major shareholders have expressed their support for the scheme.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company focusing on developing and manufacturing branded and generic products, particularly in the women’s health and dermatology sectors. The company aims to improve patient access to medications through a refined US channel strategy.
YTD Price Performance: 31.25%
Average Trading Volume: 3,158
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $275.3M
For an in-depth examination of MYX stock, go to TipRanks’ Stock Analysis page.
